Patients Stopping Weight-Loss Medications Put On Weight at a Quadrupled Rate Compared to Dieters

New research suggests that people who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who end conventional diet and exercise programs.

Research printed in a major health publication points out that while overweight people can lose a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of 0.8 kg per month after stopping.

"Users using such medications should be cognizant of the danger of fast weight regain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.

This pace of recovery implies a reversion to starting mass within about one and a half years.

Weighing Therapies

The research, which examined dozens of trials involving over 9,000 of participants, compared the outcomes of these new drugs with other pills.

The team emphasize that individuals who shed pounds through dieting generally see a slower weight regain—approximately 100 grams monthly—once they finish.

The Reason for the Fast Rebound

Experts propose the mechanism of the injections explains the amplified regain.

These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this medication means appetite is uncontrolled, making overeating far more likely."

A Chronic Condition?

Medical guidelines recommend the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.

A number of clinicians contend that, given the likelihood of weight regain, the therapy should be considered long-term.

This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the persistent nature of excess weight," comparing it to managing diseases like hypertension.

Patient Accounts

Individuals who have come off the jabs describe a sudden return of appetite.

"I experienced a switch activating and you become starving," recalled one woman.

The struggle is worsened if individuals have not established permanent dietary or behavioural changes during therapy.

Growing Interest

Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Use is more common among females than males.
• The middle-aged demographic shows the greatest usage rates.
• Many obtain the drugs through private prescriptions rather than public health services.

In conclusion, clinicians stress that while the jabs are powerful agents for weight loss, they are not a permanent cure and long-term success likely depends on integrated lifestyle support.